Madhu Kumar
Stock Analyst at Goldman Sachs
(2.84)
# 1,592
Out of 5,154 analysts
142
Total ratings
55.1%
Success rate
19.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $182.01 | +1.64% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $8.17 | -26.56% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $8.57 | +98.37% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $2.00 | +100.00% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $253.69 | -38.90% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $60.41 | -12.27% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $10.05 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $59.82 | +22.03% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $20.07 | +602.54% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $22.07 | +54.06% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $5.13 | +16.96% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $7.11 | +96.91% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $27.82 | -82.03% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.00 | +300.00% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $13.60 | +554.41% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $8.40 | +1,328.57% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $13.44 | +532.44% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $3.56 | +995.51% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $14.27 | +299.44% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.53 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.90 | +99,877.78% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $9.55 | +109.42% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.25 | +39,708.92% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $45.29 | -22.72% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $15.75 | +153.97% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $28.27 | +1,682.81% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $320.66 | -28.27% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $12.07 | +9,220.63% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.97 | +4,023.71% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $29.27 | -26.55% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $56.50 | -58.41% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $182.01
Upside: +1.64%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $8.17
Upside: -26.56%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $8.57
Upside: +98.37%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $2.00
Upside: +100.00%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $253.69
Upside: -38.90%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $60.41
Upside: -12.27%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $10.05
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $59.82
Upside: +22.03%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $20.07
Upside: +602.54%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $22.07
Upside: +54.06%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $5.13
Upside: +16.96%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $7.11
Upside: +96.91%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $27.82
Upside: -82.03%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.00
Upside: +300.00%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $13.60
Upside: +554.41%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $8.40
Upside: +1,328.57%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $13.44
Upside: +532.44%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $3.56
Upside: +995.51%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $14.27
Upside: +299.44%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.53
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.90
Upside: +99,877.78%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $9.55
Upside: +109.42%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.25
Upside: +39,708.92%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $45.29
Upside: -22.72%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $15.75
Upside: +153.97%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $28.27
Upside: +1,682.81%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $320.66
Upside: -28.27%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $12.07
Upside: +9,220.63%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $0.97
Upside: +4,023.71%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $29.27
Upside: -26.55%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $56.50
Upside: -58.41%